The General Data Protection Regulation (GDPR) is a regulation in EU law on data protection and privacy for all individuals within the European Union (EU) and the European Economic Area (EEA). Its implementation in May 2018 has had a significant impact on research, particularly in the context of real-world evidence (RWE).
RWE refers to data collected outside of the traditional clinical trial setting, such as electronic health records (EHRs), claims data, and patient-generated data. RWE is increasingly being used to support regulatory decisions and to inform clinical practice. However, the use of RWE must comply with GDPR, which has implications for the collection, processing, and use of personal data in research.
Under GDPR, personal data must be collected and processed lawfully, fairly, and transparently, and individuals have the right to be informed about how their data is being used. This means that researchers must obtain explicit and informed consent from individuals to use their personal data for research purposes. In addition, the data must be pseudonymized or anonymized to protect individuals’ privacy.
GDPR has also increased the administrative burden for researchers, who must ensure that their data management practices are compliant with GDPR. This includes developing and implementing policies and procedures for data protection, privacy, and security, as well as appointing a Data Protection Officer to oversee data management activities.
Overall, GDPR has had a positive impact on research by increasing transparency and protecting the privacy of individuals whose data is used in research. However, compliance with GDPR can be challenging, particularly in the context of RWE, where large volumes of data are collected from multiple sources. It is essential for researchers to work closely with data protection and privacy experts to ensure that their research practices are compliant with GDPR.
Share this story...
Real World Evidence (RWE) 101 – HIPAA
RWE 101 - HIPAA HIPAA (Health Insurance Portability and Accountability Act), enacted in 1996, is a federal law in the United States that establishes regulations for the protection of [...]
Real World Evidence (RWE) 101 – The Common Rule
RWE 101 - The Common Rule The Common Rule plays a significant role in the governance of observational studies. The Common Rule refers to a set of regulations and [...]
Real World Evidence (RWE) 101 – The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule)
RWE 101 - The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule) The Tuskegee Syphilis Study, conducted from 1932 to 1972, stands as [...]
Real World Evidence (RWE) 101 – Observational Study vs Non-Interventional Study
RWE 101 - Observational Study vs Non-Interventional Study In the context of real-world evidence (RWE), the terms "observational study" and "non-interventional study" are often used interchangeably to refer to [...]
Real World Evidence (RWE) 101 – Are Non-Interventional Studies Regulated?
RWE 101 - Are Non-Interventional Studies Regulated? Yes, non-interventional studies (NIS) are regulated. While the specific regulations and requirements may vary by country, there are generally guidelines and provisions [...]
Real World Evidence (RWE) 101 – Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS)
RWE 101 - Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS) In the context of real-world evidence (RWE) and regulatory frameworks, postmarket requirements (PMRs) and post-authorization safety studies (PASS) [...]







